<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND &amp; AIMS: Radiofrequency ablation (RFA) is safe and effective for eradicating <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> and <z:hpo ids='HP_0002664'>neoplasia</z:hpo> in patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We sought to assess the safety and efficacy of RFA in conjunction with baseline endoscopic resection for high-grade intraepithelial <z:hpo ids='HP_0002664'>neoplasia</z:hpo> (HGIN) and early <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: This multicenter, prospective cohort study included 24 patients (mean age, 65 years; median <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, 8 cm), with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> of &lt; or =12 cm containing HGIN or early <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, from 3 European tertiary-care medical centers </plain></SENT>
<SENT sid="3" pm="."><plain>Visible lesions were endoscopically resected, followed by serial RFA </plain></SENT>
<SENT sid="4" pm="."><plain>Focal escape endoscopic resection was used if Barrett tissue persisted despite RFA </plain></SENT>
<SENT sid="5" pm="."><plain>Complete response, defined as <z:hpo ids='HP_0000001'>all</z:hpo> biopsies negative for <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> and <z:hpo ids='HP_0002664'>neoplasia</z:hpo>, was assessed during endoscopy with 4-quadrant biopsies taken every 1 cm of the original Barrett's segment 2 months after the patient was last treated </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Twenty-three patients underwent pre-RFA endoscopic resection for visible lesions; 16 patients had early <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and 7 patients had HGIN </plain></SENT>
<SENT sid="7" pm="."><plain>The worst residual histology results, pre-RFA (after any endoscopic resection) were: HGIN (10 patients), low-grade intraepithelial <z:hpo ids='HP_0002664'>neoplasia</z:hpo> (11 patients), and <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> (3 patients) </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0002664'>Neoplasia</z:hpo> and <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> were eradicated in 95% and 88% of patients, respectively; after escape endoscopic resection in 2 patients, rates improved to 100% and 96%, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>Complications after RFA included <z:hpo ids='HP_0002249'>melena</z:hpo> (n = 1) and <z:hpo ids='HP_0002015'>dysphagia</z:hpo> (n = 1) </plain></SENT>
<SENT sid="10" pm="."><plain>After additional follow-up (median, 22 months; interquartile range, 17.2-23.8 months) no <z:hpo ids='HP_0002664'>neoplasia</z:hpo> recurred </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: This European multicenter study to show that early <z:hpo ids='HP_0002664'>neoplasia</z:hpo> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> can be effectively and safely treated with RFA, in combination with prior endoscopic resection of visible lesions </plain></SENT>
</text></document>